Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC. Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma. Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting. Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists. Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC. Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC. Dr. Calvo offers insights on an interim analysis of the atezobladderpreserve phase 2 clinical trial in MIBC. Drs. Joshua and Wallis contextualize the Metformin Active Surveillance Trial for management of low-risk prostate cancer. 177Lu-PSMA-617 in heavily pretreated patients with late-stage mCRPC provided beneficial antitumor effects. Intensified RLT with escalation of the first 3 cycles to 10-11 GBq for high-volume mCRPC may increase treatment efficacy. The use of 89Zr PET/CT and subsequent surgery in patients treated with it demonstrated low radiation exposure levels. Dr. Tawagi considers how "favorable" and "very favorable" risk alters her approach to patient management for aRCC. Dr. Tawagi opines on whether the high rates of crossover in the PSMAfore control arm limit the applicability of the results. Dr. Tawagi provides an update as to when SG or chemotherapy should be preferred for patients who do not respond to EV/pembro. Dr. Tawagi describes how she is using ctDNA in her practice in the EV/pembro setting, and how frequently she is ordering it. Dr. Tawagi explains the treatment options available for patients with metastatic bladder cancer who already have neuropathy. Drs. Morgans, Wallis dissect the association between PSA level of < 0.2 ng/mL and risk of radiological progression in ... Dr. Grivas offers long-term outcomes from the JAVELIN Bladder 100 study pertaining to specific patient populations. Dr. Grivas provides an update on relevant clinical trial updates and data readouts pertaining to urothelial carcinoma. Dr. Apolo shares the trials in progress she presented at this year's meeting, including SMART, LASER, and E-VIRTUE.